SCHEMBL4337189

SCHEMBL4337189

COc1ccc(CC(OC(C)C)C(=O)O)cc1NC(=O)COc1ccc(Cl)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
RAB9A P51151 2/20 0.52
NPC1 O15118 1/20 0.52
MAPK10 P53779 1/20 0.52
SMN1; SMN2 Q16637 4/20 0.50
HTT P42858 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
LMNA P02545 1/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
TP53 P04637 1/20 0.47
POLB P06746 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RECQL P46063 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4329366 0.92 SMN1; SMN2 (0.53) MAPTRAB9ANPC1SMN1; SMN2HTT
SCHEMBL4343560 0.85 MAPT (0.57) MAPTSMN1; SMN2HTTL3MBTL1LMNA
SCHEMBL4328777 0.84 RAB9A (0.54) MAPTRAB9ANPC1SMN1; SMN2HTT
SCHEMBL4347175 0.82 MEN1 (0.50) MAPTRAB9ANPC1MAPK10SMN1; SMN2
SCHEMBL4341964 0.82 MMP1 (0.50) MAPTLMNATDP1
SCHEMBL4328087 0.81 KMT2A (0.44) MAPTSMN1; SMN2HTTL3MBTL1LMNA
SCHEMBL4337069 0.81 PPARG (0.46) MAPTRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL4329938 0.80 KMT2A (0.52) MAPTRAB9ANPC1SMN1; SMN2HTT
SCHEMBL4337150 0.80 SMN1; SMN2 (0.41) MAPTSMN1; SMN2L3MBTL1LMNAMEN1
SCHEMBL4336292 0.80 PPARA (0.58) MAPTHTTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-20040102634-A1 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-05-27 US disclosed
EP-1380562-A1 CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102634-A1 Carboxylic acid derivative and salt thereof GPR119, IRS1, SLC5A1 MAPT 4654/4885RAB9A 2956/4885NPC1 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.